Kaiser Aluminum Corporation Reports First Quarter 2024 Financial Results
First Quarter 2024 Highlights: Net Sales $738 Million; Conversion Revenue $367 Million Net Income $25 Million; Net Income per Diluted […]
IO Biotech Announces Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic […]
Rackspace Technology to Announce First Quarter 2024 Earnings May 9, 2024
SAN ANTONIO, April 24, 2024 (GLOBE NEWSWIRE) — Rackspace Technology® (NASDAQ: RXT)— the leading end-to-end, hybrid multicloud and AI technology solutions […]
Spectral AI Schedules 2024 First Quarter Financial Results and Conference Call
DALLAS, April 24, 2024 (GLOBE NEWSWIRE) — Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence […]
Landstar System Reports First Quarter Revenue of $1.171B and Earnings Per Share of $1.32
JACKSONVILLE, Fla., April 24, 2024 (GLOBE NEWSWIRE) — Landstar System, Inc. (NASDAQ: LSTR) (“Landstar” or the “Company”) today reported basic […]
FreightCar America, Inc. To Release First Quarter Results On May 8, 2024
CHICAGO, April 24, 2024 (GLOBE NEWSWIRE) — FreightCar America, Inc. (NASDAQ: RAIL), a diversified manufacturer of railroad freight cars, today […]
FreightCar America, Inc. to Present at Planet MicroCap Showcase: VEGAS 2024
CHICAGO, April 24, 2024 (GLOBE NEWSWIRE) — FreightCar America, Inc. (Nasdaq: RAIL), a diversified manufacturer of railroad freight cars, today […]
Hawthorn Bancshares Reports First Quarter 2024 Results
JEFFERSON CITY, Mo., April 24, 2024 (GLOBE NEWSWIRE) — Hawthorn Bancshares, Inc. (NASDAQ: HWBK), (the “Company”), the bank holding company […]
VEON Announces 2024 AGM and Board Nominees
Amsterdam, 24 April 2024 – VEON Ltd. (NASDAQ: VEON, Euronext Amsterdam: VEON), a global digital operator that provides converged connectivity and […]
SpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
– Results from Phase 2b ReNeu trial of mirdametinib in NF1-PN accepted for oral presentation – – Additional data from the […]
